SVB Wealth LLC decreased its position in shares of Amarin Co. plc (NASDAQ:AMRN – Free Report) by 33.3% during the 1st quarter, Holdings Channel.com reports. The fund owned 40,000 shares of the biopharmaceutical company’s stock after selling 20,000 shares during the period. SVB Wealth LLC’s holdings in Amarin were worth $36,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently bought and sold shares of AMRN. BNP Paribas Financial Markets raised its stake in Amarin by 104.8% in the first quarter. BNP Paribas Financial Markets now owns 932,173 shares of the biopharmaceutical company’s stock valued at $830,000 after buying an additional 476,996 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Amarin by 351.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 44,599 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 34,725 shares during the period. Vanguard Personalized Indexing Management LLC boosted its holdings in Amarin by 100.6% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 46,480 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 23,313 shares in the last quarter. LCM Capital Management Inc boosted its position in Amarin by 5.1% during the fourth quarter. LCM Capital Management Inc now owns 740,159 shares of the biopharmaceutical company’s stock worth $644,000 after purchasing an additional 36,000 shares in the last quarter. Finally, Hayek Kallen Investment Management raised its position in Amarin by 63.3% during the fourth quarter. Hayek Kallen Investment Management now owns 1,016,760 shares of the biopharmaceutical company’s stock worth $885,000 after acquiring an additional 394,117 shares during the last quarter. 22.25% of the stock is currently owned by hedge funds and other institutional investors.
Amarin Stock Down 12.9 %
Shares of NASDAQ:AMRN opened at $0.68 on Thursday. Amarin Co. plc has a fifty-two week low of $0.63 and a fifty-two week high of $1.37. The firm has a 50-day simple moving average of $0.76 and a 200 day simple moving average of $0.93.
Wall Street Analyst Weigh In
A number of analysts recently commented on the company. StockNews.com lowered Amarin from a “buy” rating to a “hold” rating in a research note on Thursday, July 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Amarin in a research report on Tuesday, June 18th.
View Our Latest Stock Report on AMRN
Amarin Company Profile
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Featured Articles
- Five stocks we like better than Amarin
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 3 AI Stocks That You Can Buy and Hold Forever
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- As The Magnificent 7 Stumble, Pivot to These 3 Growth Stocks
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Joby Aviation Stock: The Case for Upside Just Got Stronger
Want to see what other hedge funds are holding AMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amarin Co. plc (NASDAQ:AMRN – Free Report).
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.